Physician profile
Patrick C Carr
NPI 1790216653
$3,694.76
in general payments reported to CMS, 2019-2025
27 companies · $1,339 in 2025
The $1,339 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.33 · 2021: $202 · 2022: $107 · 2023: $880 · 2024: $1,069 · 2025: $1,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,189 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,189.06 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $753.73 | 2021-2025 | Tremfya |
| Genzyme Corporation | $665.35 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $565.07 | 2023-2025 | |
| Amgen INC. | $299.24 | 2023-2025 | Otezla, Otezla |
| Abbvie INC. | $191.67 | 2022-2025 | Skyrizi, Rinvoq |
| Ucb, INC. | $181.23 | 2024-2025 | Bimzelx |
| Kerecis Limited | $168.68 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Regeneron Healthcare Solutions, INC. | $139.96 | 2023-2024 | Dupixent |
| Stemline Therapeutics INC. | $109.80 | 2021 | |
| Allergan, INC. | $97.33 | 2019 | |
| Leo Pharma INC. | $87.85 | 2023-2025 | Adbry, Anzupgo |
| Incyte Corporation | $67.82 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $64.09 | 2022-2025 | |
| Biofrontera INC. | $36.69 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Arcutis Biotherapeutics, INC. | $29.46 | 2025 | Zoryve |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $27.19 | 2025 | |
| Mylan Institutional INC. | $25.27 | 2023 | Hulio |
| Organogenesis INC. | $25.04 | 2025 | Via Matrix |
| Almirall LLC | $22.33 | 2023 | Klisyri |
| E.R. Squibb & Sons, L.L.C. | $19.24 | 2025 | Sotyktu |
| Lilly USA, LLC | $18.38 | 2023 | Taltz |
| Galderma Laboratories, L.P. | $17.87 | 2025 | Nemluvio |
| Genentech USA, INC. | $17.37 | 2024 | Xolair |
| Verrica Pharmaceuticals INC. | $17.33 | 2023 | Ycanth |
| Pfizer INC. | $16.65 | 2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.47 | 2024 | Cabtreo |
| Janssen Scientific Affairs, LLC | $14.65 | 2024 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Carr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.